Takeda has appointed Julie Kim as Representative Director, President, and Chief Executive Officer. In her new role, she will lead the company's global strategy as Takeda continues advancing its portfolio of innovative medicines, strengthening its research and development pipeline, and driving long-term growth across global markets. Her appointment completes the company's planned leadership succession following the retirement of Christophe Weber.
Kim joined Takeda in 2019 through the acquisition of Shire and has held several senior leadership positions within the company. Most recently, she served as President of Takeda's U.S. Business Unit and previously led the Plasma-Derived Therapies Business Unit. Before joining Takeda, she held commercial and market access leadership roles at Shire, building extensive experience across the global biopharmaceutical industry.
Why this matters: Julie Kim's appointment marks a significant milestone for Takeda as it enters its next phase of leadership under an executive with deep operational and commercial experience across its largest business units. Her promotion also reflects the growing emphasis on succession planning and leadership continuity among global pharmaceutical companies as they navigate innovation, patent cycles, and expanding healthcare demand.
Join the conversation on LinkedInConnect with Julie Kim on LinkedIn
